Refine by
Bipolar Disorder Articles & Analysis: Older
14 news found
Advancements in Mental Health with Antipsychotic APIs Protheragen-ING’s antipsychotic APIs are for the serious conditions of schizophrenia and bipolar disorder. These APIs are mostly regulators of neurotransmitters such as dopamine and serotonin, which are central to mental stability. ...
The iGEM (International Genetically Engineered Machine) Competition is an annual event in synthetic biology. Teams participating in iGEM typically spend several months conducting research, designing their projects, and building their biological systems. These projects can range from addressing real-world problems in areas such as healthcare, environmental sustainability, and manufacturing, to ...
The PTR platform has the opportunity to be used for delivery of medications in other large markets, including anxiety (CTx-2103 in development), insomnia, depression, bipolar disorder, Parkinson’s disease, xerostomia (dry mouth), migraine, and hypothyroidism. ...
The Company’s commercial product, IGALMI™ (developed as BXCL501), is a proprietary, sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The safety and effectiveness of IGALMI has not been established beyond 24 hours from the first dose. ...
BioXcel Therapeutics believes that BXCL501 potentially targets an important mediator of agitation, and the Company has observed anti-agitation results in multiple clinical studies across several neuropsychiatric disorders. BXCL501 is under investigation for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia ...
The Company’s commercial product, IGALMI™ (developed as BXCL501), is a proprietary, sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The safety and effectiveness of IGALMI has not been established beyond 24 hours from the first dose. ...
Frances Levin, Professor of Psychiatry at Columbia University and Chief of the Division on Substance Use Disorders at New York State Psychiatric Institute/Columbia University, Multiple Principal Investigator of the study and Project Director for the grant. ...
VeriSIM Life (VeriSIM), the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced that it has entered into a partnership agreement with Total Brain, an applied, integrative neuroscience company, to create breakthrough neurodata-driven actionable insights for developing novel drugs to treat a wide range of neurological ...
“We believe the recent FDA approval of BXCL501 for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults has laid a strong foundation for pursuing this Alzheimer’s-related agitation program to potentially address this debilitating symptom for patients. ...
“For BioXcel Therapeutics, this is the logical next step as we advance our five-year vision of becoming the premier AI-driven neuroscience company, exemplified by the recent FDA approval of IGALMI™ for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. For our immuno-oncology assets, we believe this ...
“There are large numbers of patients who experience agitation associated with schizophrenia and bipolar disorders, and this condition has been a long-standing challenge for healthcare professionals to treat,” said Dr. ...
In a new agreement with Saladax Biomedical, Inc., Beckman Coulter will distribute the tests designed to measure blood levels of antipsychotic drugs prescribed to treat patients with serious mental illness (SMI), such as Schizophrenia and Bipolar Disorder. These new assays are developed using an innovative nanoparticle technology and empower health care ...
Results from a newly released survey provide insights from adults living with bipolar I disorder (BD-I)* in the United States (U.S.) on the burden of living with this serious mental health condition and their experiences with treatment. ...
ByAlkermes
Our MHFA instructors deliver training in four manageable chunks, each with a focus on how to apply Mental Health First Aid Skills: Session 1 Mental Health First Aid, mental health and depression Session 2 Depression (cont.) and suicidal crisis Session 3 Anxiety, personality disorders, eating disorders and self-harm Session 4 Psychosis, ...